Company Overview and News
KUALA LUMPUR (Aug 16): Handal Resources Bhd narrowed its net loss to RM984,000 in the second quarter ended June 30, 2018 (2QFY18), from RM1.3 million a year ago, mainly due to higher revenue and higher operating income for majority of its business segments.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF BSMAF 7253 1818
KUALA LUMPUR: Handal Resources Bhd group managing director (MD) Sunildeep Singh Dhaliwal has upped his stake in the offshore crane services company to 11.12%, after acquiring an additional six million shares or a 3.76% stake via an off-market deal yesterday.
KUALA LUMPUR (Aug 9): Handal Resources Bhd group managing director (MD) Sunildeep Singh Dhaliwal has upped his stake in the offshore crane services company to 11.12%, after acquiring an additional 6 million shares or a 3.76% stake via an off-market deal today.
KUALA LUMPUR (Aug 8): Handal Resources Bhd group managing director (MD) Sunildeep Singh Dhaliwal is likely to build up his stake in the offshore crane services company after emerging as a substantial shareholder recently.
BSMAF 7253 1818
KUALA LUMPUR (July 30): Based on corporate announcements and news flow today, companies in focus on Tuesday (July 31) may include: Top Glove Corp Bhd, JAKS Resources Bhd, Star Media Group Bhd, Malaysia Building Society Bhd, Barakah Offshore Petroleum Bhd, Handal Resources Bhd, Fima Corp Bhd, Datasonic Group Bhd, New Hoong Fatt Holdings Bhd, Rev Asia Bhd and Tadmax Resources Bhd
6084 7251 7060 7113 TPGVF 1171 0173 7253 4022 TGLVY 5216 4723 WWDH
KUALA LUMPUR (July 30): Handal Resources Bhd announced today that Sunildeep Singh Dhaliwal will be taking over the position of group managing director effective immediately.
KUALA LUMPUR (July 30): Loss-making company Handal Resources Bhd's shares were up as much as 8.16%, after two directors indicated their intention to deal in the offshore crane manufacturing and servicing company's securities during the closed period, amid talks of boardroom changes.
BSMAF 7253 1818
KUALA LUMPUR: Handal Resources Bhd has attracted a number of private investors to take up stakes in the offshore crane manufacturing and servicing company in recent times even though it has been reporting losses annually since the financial year 2016 (FY16) ended Dec 31, 2016.
BSMAF 7253 1818
KUALA LUMPUR: Handal Resources Bhd’s 51%-owned subsidiary Handal Simflexi Sdn Bhd (HSSB) has entered into an initial stage of technology collaboration with Petroliam Nasional Bhd’s (Petronas) research and development (R&D) arm Petronas Research Sdn Bhd to develop subsea technology solutions.
BSMAF 7253 1818
In May, Wah Seong Corp Bhd group managing director and CEO Chan Cheu Leong(pic) also emerged as a substantial shareholder after he acquired 12.05 million shares or a 7.55% stake in the company. He later accumulated more shares in the company through the open market and now owns 17.23 million shares or a 10.8% stake in Handal.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...